Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Bullet points for Lead Compound NP-120, NP-135, NP-160, NP-178, & NP-251

November 1, 2018 - April 1, 2019 (6 Months)

NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories.

NP-178 showed positive results in a recently completed study investigating its therapeutic effects in an ulcerative colitis mouse model.

NP-135 showed positive results in a recently completed study investigating its therapeutic effects in a unilateral ureteral obstruction mouse model of kidney fibrosis.

NP-178, its lead compound for the treatment of ulcerative colitis (UC), performed equivalent to and in some measurements, better than 5-ASA, a current global standard of care treatment for inflammatory bowel disease (IBD).

In addition, the Company announces the discovery of a second compound, NP-120 that was also active in both of the Company’s UC and CD in vivo studies. Both NP-178 and NP-120 are currently used clinically for the treatment of neurological diseases.

..is pleased to announce that in a new recent in vivo animal study for Chronic Kidney Disease (CKD), the activity of NP-135 was confirmed, and two additional compounds, NP-160 and NP-251 were identified as new lead compounds in a unilateral ureteral obstruction (UUO) mouse model of kidney fibrosis.

NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has been screening for new therapeutic uses as part of its drug repurposing strategy.

...is pleased to announce that based on positive preliminary data from its first idiopathic pulmonary fibrosis (IPF) study, the Company has decided to conduct further research on compound NP-251.

NP-135, one of its lead compounds for non-alcoholic steatohepatitis (“NASH”), showed that in addition to being metabolically neutral in a number of important measurements, it further demonstrated a 34.6% reduction of a key secondary marker of fibrosis, liver hydroxyproline. The analysis was part of a recently completed pre-clinical study for NASH that used the widely accepted STAM™ mouse model from SMC Laboratories.

How will the next 6 Months shape up...


/////AMG